跳至主要内容
临床试验/NCT01000740
NCT01000740已完成4 期

An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

AstraZeneca9 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2009年8月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
59
试验地点
9
主要终点
Describe the quality of life of long-term survivors who are not terminated from the EAP

研究概览

简要总结

The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Provision of informed consent prior to any study specific procedures.
  • Participated in the Iressa EAP in China.
  • Diagnosed as NSCLC.
  • Patients who started EAP at least 3 years before this study initiated and have not yet terminated from the EAP (active long-term survivors).
  • Patients who consent to provide blood sample and available archival tumour tissue sample for EGFR gene testing (provision of tumour tissue sample is optional).

排除标准

  • Patients who disagree to participate this study.
  • Patients in whose medical objection was recorded to use the existing data from medical practice for scientific research.

结局指标

主要结局

Describe the quality of life of long-term survivors who are not terminated from the EAP

次要结局

  • To describe the current tumour control status via RECIST
  • To collect the risk factors related to prognosis in addition to the information already collected from EAP (age, gender, histology, smoking history, previous history of anti-cancer treatment, disease stage before starting gefitinib treatment, etc.)
  • To describe the treatment compliance of gefitinib in these patients
  • To describe the current clinical status of long-term survivors in the EAP program by clinical
  • To compare the key clinical features (age group, gender, histology, smoking history, disease stage, treatment-naive or pre-treated, response to prior chemotherapy,) in fast-progressors versus long-term survivals.

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (9)

Loading locations...

相似试验